List of Excipients in Branded Drug POLOCAINE

« Back to Dashboard

Generic Drugs Containing POLOCAINE

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	mepivacaine hydrochloride	50090-4408	HYDROCHLORIC ACID
A-S Medication Solutions	mepivacaine hydrochloride	50090-4408	METHYLPARABEN
A-S Medication Solutions	mepivacaine hydrochloride	50090-4408	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in POLOCAINE?

# Of NDCs	Excipient
5	HYDROCHLORIC ACID
3	METHYLPARABEN
5	SODIUM CHLORIDE

POLOCAINE Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 11, 2026

POLOCAINE is a legacy brand of mepivacaine hydrochloride injection used for local and regional anesthesia. Its commercial value is driven by supply reliability, preservative-free presentation, dental and injectable-device formats, and manufacturing economics rather than meaningful molecule-level exclusivity. The strongest product opportunities are likely to come from differentiated packaging, ready-to-use presentations, stability improvements, and targeted institutional supply agreements.

What is POLOCAINE and which active ingredient does it contain?

POLOCAINE contains mepivacaine hydrochloride, an amide local anesthetic. Products have been marketed primarily in 2% and 3% injectable strengths.

Product attribute	POLOCAINE profile
Active ingredient	Mepivacaine hydrochloride
Therapeutic class	Amide local anesthetic
Main uses	Infiltration, peripheral nerve block, epidural and caudal anesthesia, dental anesthesia
Common concentrations	2% and 3%
Route	Injection
Preservative-free version	POLOCAINE-MPF
Conventional product	POLOCAINE, historically containing methylparaben in multidose presentations
Primary commercial channels	Dental, ambulatory surgery, hospitals, anesthesia practices
Regulatory pathway for competitors	Generally ANDA for equivalent products; 505(b)(2) may apply to materially different formulations or presentations

Mepivacaine is supplied as a sterile aqueous solution. The drug is commonly selected when clinicians want a shorter or intermediate duration of anesthesia than bupivacaine and when avoidance of vasoconstrictors is preferred.

What excipients are used in POLOCAINE formulations?

The principal excipient distinction is between preserved and methylparaben-free products.

POLOCAINE conventional formulation

Traditional POLOCAINE multidose presentations have used methylparaben as an antimicrobial preservative. The formulation also requires pH adjustment and may contain sodium chloride depending on the specific product presentation.

Typical formulation elements include:

• Mepivacaine hydrochloride
• Water for injection
• Methylparaben in preserved multidose formats
• Sodium chloride where required for tonicity
• Hydrochloric acid or sodium hydroxide for pH adjustment

The precise excipient composition varies by strength, container, and product version. Commercial formulation work should rely on the current FDA-approved labeling and product-specific chemistry, manufacturing and controls documentation rather than historical brand descriptions.

POLOCAINE-MPF

POLOCAINE-MPF is a methylparaben-free presentation intended for single-dose use or settings where preservative exposure is undesirable.

Its commercial attributes include:

• No methylparaben
• Sterile aqueous formulation
• Tonicity adjustment where applicable
• pH adjustment
• Single-dose vial, ampule, or cartridge compatibility depending on product format

Preservative-free local anesthetics are particularly relevant to neuraxial and epidural procedures, where preservative avoidance is an important formulation and labeling consideration. The preservative-free claim must be supported by validated sterility, container-closure integrity, and microbiological controls.

What excipient strategy offers the strongest commercial opportunity?

The strongest opportunity is not a new excipient for its own sake. It is a differentiated presentation that improves safety, workflow, shelf life, or compatibility with clinical devices.

Preservative-free, ready-to-use products

A preservative-free mepivacaine product can compete in:

• Regional anesthesia
• Epidural and caudal procedures
• Ambulatory surgery
• Dental cartridges
• Hospital formularies seeking standardized single-dose products

The commercial advantage is operational. Single-dose formats reduce manipulation, simplify medication-use protocols, and avoid the need to manage multidose containers in procedure areas.

Low-extractables container systems

Mepivacaine hydrochloride is an aqueous injectable and may interact with elastomeric closures, cartridge components, or plastic contact materials over extended storage. A product using low-extractables and low-leachables components could support hospital and dental procurement requirements.

Potential differentiators include:

• Fluoropolymer-coated elastomer stoppers
• Low-adsorption syringe components
• Glass cartridges with validated plunger systems
• Ready-to-use prefilled syringes
• Improved container-closure integrity
• Reduced particulate burden

These features may be protectable through device, packaging, manufacturing, or combination-product claims even when the formulation itself is conventional.

Buffered formulations

Mepivacaine solutions require pH control to preserve stability and tolerability. A buffered formulation could improve injection comfort or reduce variability after storage, but the commercial case depends on demonstrating a clinically meaningful benefit.

Potential development targets include:

• Reduced injection pain
• Narrower pH drift over shelf life
• Improved stability after vial puncture
• Compatibility with dental cartridge systems
• Reduced precipitation risk when used with compatible adjuncts

A buffered product should not be assumed to have a regulatory advantage. The sponsor would need comparative stability, compatibility, local tolerance, and, depending on the formulation change, clinical or bridging data.

Antioxidant-free strategy

Mepivacaine hydrochloride does not require the same antioxidant strategy as oxidation-sensitive drug substances. Adding sulfites or other antioxidants could introduce tolerability and labeling issues without a clear benefit.

An antioxidant-free formulation has a commercial rationale where it can be supported by:

• Validated oxygen-control packaging
• Headspace management
• Light-protective containers
• Long-term and accelerated stability data
• Low-peroxide excipient controls

The preferred strategy is usually to avoid unnecessary excipients and control degradation through packaging and manufacturing.

What patents protect POLOCAINE and mepivacaine products?

POLOCAINE is based on an old small-molecule active ingredient. Public FDA product information does not indicate a commercially important, current patent estate around mepivacaine itself. The principal barriers to competition are manufacturing, sterile filling, regulatory compliance, supply reliability, and market access.

IP category	Likely strength for POLOCAINE
Mepivacaine composition of matter	Expired or commercially irrelevant
Basic injectable solution	Weak if based on conventional excipients
Preservative-free formulation	Potentially protectable, but difficult to make broad and enforceable
Buffered formulation	Potentially protectable if tied to specific pH, stability, or performance data
Dental cartridge	Moderate device and packaging opportunity
Prefilled syringe	Moderate device, filling, and container opportunity
Manufacturing process	Potentially valuable if it improves sterility assurance, yield, or stability
Trade secret controls	Important for process parameters, container preparation, and quality systems
Brand and trade dress	Commercially relevant but separate from pharmaceutical patent protection

A new product may obtain patents on narrowly defined formulations, container systems, or manufacturing processes. Broad claims covering "mepivacaine plus a conventional buffer" would face substantial validity and obviousness risk because aqueous local-anesthetic formulations are well established.

When does POLOCAINE lose exclusivity?

POLOCAINE does not appear to depend on a current molecule patent or meaningful statutory exclusivity period. Mepivacaine hydrochloride has been marketed for decades, and generic injectable competition has existed in the United States.

The relevant exclusivity framework is therefore:

Exclusivity type	Assessment
New chemical entity exclusivity	Not applicable to this legacy active ingredient
Orphan exclusivity	Not applicable
Pediatric exclusivity	No commercially relevant period identified
Active Orange Book patent	No current commercially significant listing identified from public product materials
Brand exclusivity	Brand recognition and supply contracts, not statutory exclusivity
Formulation exclusivity	Possible only for a genuinely new, approved formulation
Device or packaging protection	Potentially available through separate patent filings

FDA approval of a generic mepivacaine injection would generally proceed through an ANDA if the product matches the reference product in active ingredient, dosage form, strength, route, and relevant quality attributes. A materially different formulation or delivery system could require a 505(b)(2) application.

What is the Orange Book status of POLOCAINE?

The Orange Book identifies FDA-approved drug products, reference-listed drugs, patents, and exclusivity information. POLOCAINE's commercial position should be assessed at the application and dosage-form level rather than by brand name alone.

Publicly available FDA labeling identifies legacy POLOCAINE and POLOCAINE-MPF products, while generic mepivacaine hydrochloride injections have been marketed separately. The key Orange Book questions are:

1. Which POLOCAINE application is listed as the reference product?
2. Is the relevant presentation active or discontinued?
3. Are any patents listed for the specific application?
4. Does the proposed generic rely on a current reference-listed drug?
5. Does the formulation require an ANDA or 505(b)(2) strategy?

For a legacy injectable, the absence of an active patent listing generally makes Paragraph IV litigation less likely than in branded small-molecule products with live composition or method patents.

Which companies are challenging POLOCAINE?

Competition has historically come from generic injectable manufacturers rather than from a concentrated patent challenge to a single active brand. Generic mepivacaine products can compete on:

• 1% versus 2% versus 3% strength
• Preserved versus preservative-free formulation
• Single-dose versus multidose packaging
• Vial, ampule, cartridge, or syringe format
• Hospital contract pricing
• Dental distribution
• Supply continuity

Potential competitors include established generic injectable companies, specialty anesthesia suppliers, and dental pharmaceutical manufacturers. The competitive threat is commercial substitution, not necessarily Paragraph IV litigation.

What Paragraph IV challenges affect mepivacaine?

No major, commercially decisive Paragraph IV dispute is associated with POLOCAINE in the public record commonly used for branded drug patent analysis. The reason is structural: mepivacaine is an old active ingredient, and the core product is not protected by a visible, high-value patent thicket.

A Paragraph IV strategy could still arise against a newly approved formulation if a sponsor obtains patents covering:

• A narrow pH range
• A specific preservative-free composition
• A stability profile
• A cartridge or syringe system
• A co-packaged anesthetic kit
• A manufacturing process

Such patents would be more vulnerable to design-around than a composition-of-matter patent.

What litigation and settlement risks affect POLOCAINE?

The principal litigation risks are likely to involve product liability, manufacturing quality, contamination, labeling, or supply interruption rather than patent infringement.

For a new mepivacaine product, risk areas include:

• Sterility failures
• Particulate contamination
• Container-closure defects
• Incorrect concentration labeling
• Medication errors between 2% and 3% products
• Preservative-related adverse reactions
• Device malfunction in dental cartridges or prefilled syringes
• Incompatibility with other injectable agents

No major public patent settlement involving POLOCAINE is identified in the standard regulatory and patent context. A settlement would become relevant only if a new formulation or device patent created a direct infringement dispute.

What generic launch scenarios exist for POLOCAINE?

Scenario 1: Conventional ANDA launch

A manufacturer develops a pharmaceutically equivalent mepivacaine hydrochloride injection using conventional excipients and standard packaging.

Commercial profile:

• Lowest development cost
• Shortest regulatory path
• Heavy price competition
• Limited differentiation
• Dependence on manufacturing efficiency and supply reliability

Scenario 2: Preservative-free specialty launch

A manufacturer develops a preservative-free product in single-dose vials or cartridges.

Commercial profile:

• Higher unit value
• Better fit for anesthesia and dental channels
• More demanding sterility and packaging controls
• Potential hospital formulary preference
• Moderate differentiation

Scenario 3: Device-enabled launch

A sponsor develops prefilled syringes, ready-to-use cartridges, or a calibrated injection system.

Commercial profile:

• Higher development and validation cost
• Potential device and packaging IP
• Reduced preparation time
• Possible reduction in medication-use errors
• Greater regulatory complexity

Scenario 4: 505(b)(2) formulation

A sponsor develops a product with a new buffer system, delivery device, concentration, or administration profile.

Commercial profile:

• Potential for formulation or clinical differentiation
• Higher evidence burden than a standard ANDA
• Possible three-year exclusivity for a qualifying new clinical investigation
• Greater opportunity for patent protection
• Larger development risk

How strong is the POLOCAINE patent estate?

The POLOCAINE patent estate is weak at the active-ingredient level and limited at the conventional formulation level. A stronger modern estate would need to combine several layers:

1. Formulation claims covering a defined composition and performance range.
2. Container claims covering a validated low-leachables system.
3. Device claims covering a prefilled or cartridge-based delivery format.
4. Manufacturing claims covering sterile processing or stability improvements.
5. Method-of-use claims tied to a specific procedure or dosing protocol.

The practical strength of such an estate would depend on claim breadth, clinical relevance, freedom to operate, and whether competitors could reproduce the product using different excipients or containers.

What manufacturing and IP barriers exist?

The main barriers are operational rather than molecular.

Sterile manufacturing

Mepivacaine injection requires validated sterile processing, aseptic filling or terminal sterilization where appropriate, environmental monitoring, and container-closure integrity testing.

Concentration control

The product must control the risk of concentration mix-ups, particularly between 2% and 3% presentations. Label design, color coding, barcode verification, and segregated production can support risk reduction.

Container compatibility

The sponsor must characterize:

• Extractables and leachables
• Sorption and adsorption
• Closure integrity
• Particulate generation
• Light exposure
• In-use stability
• Compatibility with dental and anesthesia devices

Supply chain

Commercial success depends on reliable access to:

• Mepivacaine hydrochloride API
• Sterile glass or polymer containers
• Elastomeric closures
• Dental cartridge components
• Contract sterile filling capacity

A reliable supply position can support premium pricing in a market where shortages or backorders affect formulary decisions.

How does POLOCAINE compare with competing local anesthetics?

Product	Relative commercial differentiation	Excipient opportunity
Mepivacaine	Short-to-intermediate duration; commonly used without vasoconstrictor	Preservative-free, dental cartridges, ready-to-use systems
Lidocaine	Broadest familiarity and large generic base	Device convenience and specialty formulations
Bupivacaine	Longer duration; established hospital use	Liposomal and extended-release delivery systems
Ropivacaine	Regional anesthesia positioning	Premium preservative-free and institutional formats
Articaine	Strong dental relevance	Cartridge, preservative, and vasoconstrictor management

Mepivacaine's opportunity is strongest where clinicians value a reliable plain local anesthetic, dental usability, or preservative-free administration.

What revenue exposure and licensing opportunities exist?

POLOCAINE revenue is exposed to generic price erosion, tender competition, and supply substitution. A brand owner can preserve value through:

• Dental distributor contracts
• Hospital group purchasing agreements
• Preservative-free premium products
• Private-label manufacturing
• Regional licensing
• Contract development and manufacturing
• Device co-development
• Geographic rights for injectable anesthetic portfolios

The most credible licensing targets are specialty injectable companies, dental pharmaceutical suppliers, and manufacturers with sterile filling capacity. Licensing a conventional mepivacaine solution alone is unlikely to command strong economics. A package combining formulation know-how, cartridge technology, regulatory support, and supply capacity is more commercially defensible.

Key Takeaways

• POLOCAINE is a legacy mepivacaine hydrochloride injectable product with limited molecule-level exclusivity.
• The principal excipient distinction is between methylparaben-preserved POLOCAINE and preservative-free POLOCAINE-MPF.
• The strongest commercial opportunity is a preservative-free, ready-to-use, device-compatible presentation.
• Conventional formulation patents would likely be narrow and vulnerable to design-around.
• Container, cartridge, prefilled-syringe, and manufacturing patents may provide stronger practical protection.
• Generic competition is more important than Paragraph IV litigation risk.
• An ANDA is generally the most efficient pathway for a conventional equivalent product.
• A 505(b)(2) strategy may be appropriate for a materially differentiated formulation or delivery system.
• Manufacturing reliability, sterile capacity, packaging quality, and hospital contracting are central competitive advantages.
• Mepivacaine's best growth opportunities are in dental, ambulatory surgery, regional anesthesia, and preservative-free institutional supply.

FAQs

Is POLOCAINE the same as mepivacaine?

POLOCAINE is a brand associated with mepivacaine hydrochloride injection. Generic mepivacaine products may use different excipients, containers, strengths, and labeling.

Does POLOCAINE contain methylparaben?

Traditional preserved POLOCAINE presentations may contain methylparaben. POLOCAINE-MPF is the methylparaben-free version. The current product label should be used to verify the formulation for a specific presentation.

Can a company patent a new mepivacaine formulation?

Yes, but protection would generally need to rely on a defined composition, stability property, delivery system, manufacturing process, or clinically meaningful formulation feature. The active ingredient itself does not provide a strong modern patent barrier.

Is a preservative-free mepivacaine product eligible for an ANDA?

It may be, if it is pharmaceutically equivalent to the applicable reference product and meets FDA requirements. A materially different formulation, concentration, delivery system, or clinical use may require a 505(b)(2) application.

Are biosimilar rules relevant to POLOCAINE?

No. Mepivacaine hydrochloride is a small-molecule drug, not a biologic. Generic drug rules under the Hatch-Waxman framework, rather than biosimilar rules under the Biologics Price Competition and Innovation Act, apply.

References

1. DailyMed. (n.d.). Polocaine and Polocaine-MPF: Mepivacaine hydrochloride injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

4. U.S. Food and Drug Administration. (n.d.). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/types-applications/505b2-application

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.